住友及武田抗精神病药Lurasidone获瑞士医药管理局批准

2013-08-15 tomato 生物谷

日本住友制药(Dainippon Sumitomo Pharma)和武田(Takeda)今天宣布,非典型抗精神病药物鲁拉西酮盐酸盐(Lurasidone)上市许可申请(MAA)获瑞士医药管理局(Swissmedic)批准,该药用于精神分裂症(schizophrenia)的治疗。 Lurasidone是每日一次的非典型抗精神病口服治疗药物,由住友制药发现和开发。在美国,该药分别于2010年10

日本住友制药(Dainippon Sumitomo Pharma)和武田(Takeda)今天宣布,非典型抗精神病药物鲁拉西酮盐酸盐(Lurasidone)上市许可申请(MAA)获瑞士医药管理局(Swissmedic)批准,该药用于精神分裂症(schizophrenia)的治疗。

Lurasidone是每日一次的非典型抗精神病口服治疗药物,由住友制药发现和开发。在美国,该药分别于2010年10月和2013年6月获FDA批准用于精神分裂症和双相I型障碍相关严重抑郁发作的治疗。

原文链接:

Dainippon Sumitomo Pharma Co., Ltd. : DSP and Takeda Announce Approval of the Marketing Authorization Application for Atypical Antipsychotic Agent Lurasidone in Switzerland原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703488, encodeId=61c41e0348817, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Fri Dec 06 14:23:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736864, encodeId=ee831e368642f, content=<a href='/topic/show?id=53f368e21e5' target=_blank style='color:#2F92EE;'>#瑞士#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68721, encryptionId=53f368e21e5, topicName=瑞士)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874534196062, createdName=Tamikia, createdTime=Tue Oct 08 11:23:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024483, encodeId=f42f20244834f, content=<a href='/topic/show?id=b00c1110864' target=_blank style='color:#2F92EE;'>#Lurasidone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11108, encryptionId=b00c1110864, topicName=Lurasidone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Dec 27 08:23:00 CST 2013, time=2013-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793074, encodeId=b4d61e930744c, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Sun Jul 20 00:23:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408612, encodeId=17b314086121c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513043, encodeId=9e381513043f9, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-12-06 tongyongming
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703488, encodeId=61c41e0348817, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Fri Dec 06 14:23:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736864, encodeId=ee831e368642f, content=<a href='/topic/show?id=53f368e21e5' target=_blank style='color:#2F92EE;'>#瑞士#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68721, encryptionId=53f368e21e5, topicName=瑞士)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874534196062, createdName=Tamikia, createdTime=Tue Oct 08 11:23:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024483, encodeId=f42f20244834f, content=<a href='/topic/show?id=b00c1110864' target=_blank style='color:#2F92EE;'>#Lurasidone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11108, encryptionId=b00c1110864, topicName=Lurasidone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Dec 27 08:23:00 CST 2013, time=2013-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793074, encodeId=b4d61e930744c, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Sun Jul 20 00:23:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408612, encodeId=17b314086121c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513043, encodeId=9e381513043f9, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-10-08 Tamikia
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703488, encodeId=61c41e0348817, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Fri Dec 06 14:23:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736864, encodeId=ee831e368642f, content=<a href='/topic/show?id=53f368e21e5' target=_blank style='color:#2F92EE;'>#瑞士#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68721, encryptionId=53f368e21e5, topicName=瑞士)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874534196062, createdName=Tamikia, createdTime=Tue Oct 08 11:23:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024483, encodeId=f42f20244834f, content=<a href='/topic/show?id=b00c1110864' target=_blank style='color:#2F92EE;'>#Lurasidone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11108, encryptionId=b00c1110864, topicName=Lurasidone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Dec 27 08:23:00 CST 2013, time=2013-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793074, encodeId=b4d61e930744c, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Sun Jul 20 00:23:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408612, encodeId=17b314086121c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513043, encodeId=9e381513043f9, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-12-27 yyj062
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703488, encodeId=61c41e0348817, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Fri Dec 06 14:23:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736864, encodeId=ee831e368642f, content=<a href='/topic/show?id=53f368e21e5' target=_blank style='color:#2F92EE;'>#瑞士#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68721, encryptionId=53f368e21e5, topicName=瑞士)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874534196062, createdName=Tamikia, createdTime=Tue Oct 08 11:23:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024483, encodeId=f42f20244834f, content=<a href='/topic/show?id=b00c1110864' target=_blank style='color:#2F92EE;'>#Lurasidone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11108, encryptionId=b00c1110864, topicName=Lurasidone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Dec 27 08:23:00 CST 2013, time=2013-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793074, encodeId=b4d61e930744c, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Sun Jul 20 00:23:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408612, encodeId=17b314086121c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513043, encodeId=9e381513043f9, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1703488, encodeId=61c41e0348817, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Fri Dec 06 14:23:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736864, encodeId=ee831e368642f, content=<a href='/topic/show?id=53f368e21e5' target=_blank style='color:#2F92EE;'>#瑞士#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68721, encryptionId=53f368e21e5, topicName=瑞士)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874534196062, createdName=Tamikia, createdTime=Tue Oct 08 11:23:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024483, encodeId=f42f20244834f, content=<a href='/topic/show?id=b00c1110864' target=_blank style='color:#2F92EE;'>#Lurasidone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11108, encryptionId=b00c1110864, topicName=Lurasidone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Dec 27 08:23:00 CST 2013, time=2013-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793074, encodeId=b4d61e930744c, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Sun Jul 20 00:23:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408612, encodeId=17b314086121c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513043, encodeId=9e381513043f9, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-08-17 cathymary
  6. [GetPortalCommentsPageByObjectIdResponse(id=1703488, encodeId=61c41e0348817, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Fri Dec 06 14:23:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736864, encodeId=ee831e368642f, content=<a href='/topic/show?id=53f368e21e5' target=_blank style='color:#2F92EE;'>#瑞士#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68721, encryptionId=53f368e21e5, topicName=瑞士)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874534196062, createdName=Tamikia, createdTime=Tue Oct 08 11:23:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024483, encodeId=f42f20244834f, content=<a href='/topic/show?id=b00c1110864' target=_blank style='color:#2F92EE;'>#Lurasidone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11108, encryptionId=b00c1110864, topicName=Lurasidone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Dec 27 08:23:00 CST 2013, time=2013-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793074, encodeId=b4d61e930744c, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Sun Jul 20 00:23:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408612, encodeId=17b314086121c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513043, encodeId=9e381513043f9, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1703488, encodeId=61c41e0348817, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Fri Dec 06 14:23:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736864, encodeId=ee831e368642f, content=<a href='/topic/show?id=53f368e21e5' target=_blank style='color:#2F92EE;'>#瑞士#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68721, encryptionId=53f368e21e5, topicName=瑞士)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874534196062, createdName=Tamikia, createdTime=Tue Oct 08 11:23:00 CST 2013, time=2013-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024483, encodeId=f42f20244834f, content=<a href='/topic/show?id=b00c1110864' target=_blank style='color:#2F92EE;'>#Lurasidone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11108, encryptionId=b00c1110864, topicName=Lurasidone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Dec 27 08:23:00 CST 2013, time=2013-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793074, encodeId=b4d61e930744c, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Sun Jul 20 00:23:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408612, encodeId=17b314086121c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513043, encodeId=9e381513043f9, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517205, encodeId=af7a151e205f8, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63338, encryptionId=a0176333892, topicName=武田)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6da11069119, createdName=12498f17m69暂无昵称, createdTime=Sat Aug 17 08:23:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]

相关资讯

赛诺菲开发的梭状杆菌疫苗进入三期实验

赛诺菲公司疫苗研发最近喜讯不断,先是公司研发的登革热疫苗后期研究数据良好,继而又传出公司研发的梭状杆菌疫苗正式进入三期研究。 梭状杆菌一直在世界上很多国家肆虐,根据美国疾病控制中心(CDC)估计,每年约有14000名美国人死于该细菌引起的疟疾,赛诺菲公司希望能够找出一种有效手段预防梭状杆菌感染。据估计,梭状杆菌疫苗市场最高可达20亿美元,是目前规模的十倍,赛诺菲的疫苗研究进入三期阶段将有利于

FDA:葛兰素史克HIV新药Tivicay获FDA批准

葛兰素史克(GSK)8月12日宣布,FDA已批准Tivicay(dolutegravir)50mg片剂。 Tivicay为每日一次的口服药物,是HIV整合酶抑制剂,旨在与其他抗逆转录病毒制剂联合用于既往已治疗过、或初治HIV-1成人和12岁及以上体重至少40千克儿童感染者。 Tivicay新药申请(NDA)的提交,包括4个关键性III期临床试验(SPRING-2、SINGLE、SAILIN

FDA授予登革热纳米抗病毒药物DengueCide孤儿药地位

NanoViricides公司8月12日宣布,FDA已授予实验性药物DengueCide孤儿药地位,该药开发用于登革热(dengue)及登革出血热(dengue hemorrhagic fever)的治疗。同时,在提交DengueCide新药申请(NDA)时,将有资格获得优先审查资格。 DengueCide是一种纳米抗病毒候选药物(nanoviricide),在登革热病毒感染动物模型中已表现

FDA授予卫材淋巴瘤药物E7777孤儿药地位

卫材(Eisai)8月9日宣布,FDA已授予实验性化合物E7777用于治疗皮肤T细胞淋巴瘤(CTCL)的孤儿药地位(orphan drug status)。E7777被设计成具有一种改善的纯度属性和制造工艺,目前正处于一个关键临床试验,相关数据将用于支持相关监管申请文件的提交。 在美国,如果所开发的药物是用于少于20万患者群体的治疗,孤儿药法案(Orphan Drug Act,ODA)允许F

强生万珂(Velcade)VD和VTD诱导疗法方案获EC批准

强生(JNJ)旗下杨森-Cilag国际(Janssen-Cilag)8月9日宣布,重磅黑色素瘤药物Velcade(万珂,通用名:硼替佐米,bortezomib)联合地塞米松(dexamethasone)(VD)或沙利度胺(thalidomide)和地塞米松(VTD)的诱导疗法方案,获得了欧盟委员会(EC)的批准。 这一许可扩展,将适用于既往未治疗、且适合高剂量化疗和血液干细胞移植的多发性骨髓

百时美施贵宝抑郁药BMS-820836 II期试验失败

百时美施贵宝(BMS)及合作伙伴Albany Molecular  Research公司8月12日宣布,已终止实验性抑郁症药物BMS-820836的II期临床试验。该药由Albany开发,由百时美施贵宝推进临床试验。然而,临床试验中,该药未实现超过现有治疗方案的临床益处。 BMS-820836针对的是难治性抑郁症(TRD),这类患者对已上市的其他疗法不响应。在2个IIb期临床试验中